| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000260805.1 |
Cytarabine |
Bladder urothelial carcinoma |
0.001027332 |
Resistant |
| ENSG00000260805.1 |
Cytarabine |
Breast invasive carcinoma |
0.019061233 |
Resistant |
| ENSG00000260805.1 |
Cytarabine |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.001122677 |
Resistant |
| ENSG00000260805.1 |
Cytarabine |
Lung squamous cell carcinoma |
0.011255585 |
Resistant |
